HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir

BACKGROUND&AIMS: Recent clinical trials of direct-acting-antiviral agents (DAAs) against hepatitis C virus (HCV) achieved >90% sustained-virological response (SVR) rates, suggesting that cure often took place before the end of treatment (EOT). We sought to evaluate retrospectively whether ear...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Hepatol
Main Authors: Dahari, Harel, Canini, Laetitia, Graw, Frederik, Uprichard, Susan L., Araújo, Evaldo S.A., Penaranda, Guillaume, Coquet, Emilie, Riso, Aurelie, Renou, Christophe, Bourliere, Marc, Cotler, Scott J., Halfon, Philippe
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5081285/
https://ncbi.nlm.nih.gov/pubmed/26907973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2016.02.022
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares